Profile data is unavailable for this security.
About the company
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
- Revenue in USD (TTM)10.82m
- Net income in USD-67.66m
- Incorporated1990
- Employees70.00
- LocationLineage Cell Therapeutics Inc2173 Salk Avenue, Suite 200CARLSBAD 92008United StatesUSA
- Phone+1 (510) 521-3390
- Fax+1 (510) 521-3389
- Websitehttps://lineagecell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | 0.00 | -212.02m | 366.31m | 226.00 | -- | 1.15 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Aclaris Therapeutics Inc | 15.74m | -141.68m | 367.29m | 64.00 | -- | 3.06 | -- | 23.33 | -1.38 | -1.38 | 0.136 | 1.11 | 0.088 | -- | 6.27 | 245,968.80 | -79.17 | -48.16 | -90.39 | -55.11 | 3.98 | 40.68 | -900.01 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 368.34m | 305.00 | -- | 0.595 | -- | 13.00 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 374.17m | 123.00 | -- | 47.24 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -19.44m | 380.11m | 16.00 | -- | 2.68 | -- | -- | -3.44 | -3.44 | 0.00 | 21.25 | 0.00 | -- | -- | 0.00 | -25.88 | -52.66 | -26.53 | -59.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -85.50 | -- | -- | -- |
| Absci Corp | 2.82m | -114.60m | 380.44m | 156.00 | -- | 1.80 | -- | 135.15 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 383.92m | 32.00 | -- | 1.48 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Entrada Therapeutics Inc | 61.52m | -103.46m | 384.87m | 183.00 | -- | 1.13 | -- | 6.26 | -2.50 | -2.50 | 1.47 | 8.91 | 0.1272 | -- | 32.39 | 336,174.90 | -21.39 | -8.44 | -23.70 | -10.02 | -- | -- | -168.16 | -33.36 | -- | -- | 0.00 | -- | 63.38 | -- | 1,081.69 | -- | 38.04 | -- |
| Lineage Cell Therapeutics Inc | 10.82m | -67.66m | 386.95m | 70.00 | -- | 17.56 | -- | 35.78 | -0.2955 | -0.2955 | 0.0469 | 0.0957 | 0.1162 | -- | 40.66 | 154,514.30 | -72.50 | -20.81 | -81.52 | -24.54 | 97.84 | 90.99 | -624.16 | -331.61 | -- | -- | 0.004 | -- | 6.19 | 22.00 | 13.39 | -- | 5.13 | -- |
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 390.81m | 25.00 | -- | -- | -- | 417.08 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 392.66m | 27.00 | -- | 7.61 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
| Benitec Biopharma Inc | 0.00 | -41.82m | 394.49m | 19.00 | -- | 3.27 | -- | -- | -1.18 | -1.18 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -50.76 | -79.73 | -52.87 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 401.60m | 73.00 | -- | 2.20 | -- | 10.80 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 409.41m | 104.00 | 21.11 | 5.78 | 19.31 | 3.28 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
Data as of Feb 06 2026. Currency figures normalised to Lineage Cell Therapeutics Inc's reporting currency: US Dollar USD
40.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Broadwood Capital, Inc.as of 12 Nov 2025 | 57.46m | 24.95% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 8.23m | 3.58% |
| Defender Capital LLCas of 31 Dec 2025 | 6.83m | 2.97% |
| Raffles Capital Management LLCas of 30 Sep 2025 | 5.39m | 2.34% |
| Comerica Bank (Investment Management Texas)as of 31 Dec 2025 | 4.60m | 2.00% |
| Millennium Management LLCas of 30 Sep 2025 | 2.68m | 1.16% |
| Geode Capital Management LLCas of 30 Sep 2025 | 2.42m | 1.05% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.23m | 0.97% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 1.91m | 0.83% |
| Dauntless Investment Group LLCas of 30 Sep 2025 | 1.61m | 0.70% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
